Brincidofovir(Brincidofovir) - 药物靶点：UL30 x UL54_在研适应症：天花，腺病毒科感染，巨细胞病毒血症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

BCV、Brincidofovir (USAN)、Cidofovir hexadecyloxypropyl ester

+ [8]

靶点

UL30 x UL54

作用方式

抑制剂

作用机制

UL30抑制剂(人单纯疱疹病毒1型DNA聚合酶抑制剂)、UL54抑制剂(人单纯疱疹病毒5型DNA聚合酶抑制剂)

治疗领域

感染肿瘤免疫系统疾病+ [3]

在研适应症

天花腺病毒科感染巨细胞病毒血症+ [2]

非在研适应症

腺病毒感染BK病毒感染埃博拉病毒性疾病+ [2]

原研机构

Chimerix, Inc.

在研机构

SymBio Pharmaceuticals Ltd.

The University of California, San FranciscoEmergent Biodefense Operations Lansing LLC

非在研机构

Chimerix, Inc.Emergent BioDefense Operations Lansing, Inc.

National Institutes of Health

权益机构

University of California

National Cancer Centre of Singapore Pte Ltd.

SymBio Pharmaceuticals Ltd.

+ [6]

最高研发阶段批准上市

首次获批日期

美国 (2021-06-04),

天花

最高研发阶段(中国)临床1/2期

特殊审评快速通道 (美国)、孤儿药 (美国)、孤儿药 (欧盟)、孤儿药 (日本)

登录后查看时间轴

结构/序列

分子式C27H52N3O7P

InChIKeyWXJFKKQWPMNTIM-VWLOTQADSA-N

CAS号444805-28-1

关联

28

项与 Brincidofovir 相关的临床试验

NCT06761677

/ Recruiting临床1/2期

A Multi-Center, Global, Open-Label, Phase 1b/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma As Well As to Evaluate the Safety and Efficacy of Intravenous Brincidofovir in Patients With Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma Using The Recommended Phase 2 Dose

This study is a multi-center, global, open-label, Phase 1b/2 clinical study, and it will be conducted at multiple study sites in several countries, including Japan, Korea, and Singapore, to reveal the safety, tolerability, dose limiting toxicity (DLT), maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D), pharmacokinetics (PK), and preliminary efficacy of BCV in patients with relapsed or refractory lymphoma and to assess the efficacy and safety of Brincidofovir (SyB V-1901, BCV) in patients with relapsed or refractory Extranodal Natural Killer/T-cell Lymphoma (ENKL).
This study consists of 2 parts and will enroll a total (maximum) of 43 male and female participants who meet the eligibility criteria (Phase 1b part: Up to 18 participants [3 to 6 participants in each of the 3 cohorts], Phase 2 part: 25 participants).

开始日期2025-06-09

申办/合作机构

SymBio Pharmaceuticals Ltd.

NCT05935917

/ Completed临床1期

A Phase 1, Open-label, Single-dose, Randomized, Two-period, Crossover Study Evaluating the Bioequivalence of Brincidofovir Form H and Form II Tablets in Healthy Adult Participants

The goal of this clinical trial is to evaluate whether both Form H and Form II, 100mg brincidofovir tablets are bioequivalent, when given under fasting conditions in healthy adults.
Participants will be randomized to each receive one tablet of Form H and one tablet of Form II,14 days apart and undergo pharmacokinetic testing pre-dose and post-dose to evaluate safety. This is an open-label, single-dose, randomized, two-period, crossover study.

开始日期2023-05-30

申办/合作机构

Emergent BioSolutions, Inc.

NCT05511779

/ Terminated临床2期

Phase II, Open-label, Randomized, Multiple Ascending Dose Confirmation of the Safety and Tolerability of Brincidofovir in Subjects With BK Virus Infection (Viremia) After Kidney Transplantation (BASTION)

This is a Phase II, multicenter, open-label, randomized, standard of care (SOC) controlled, multiple ascending dose study to assess the safety and tolerability of IV Brincidofovir (BCV) in subjects with BKV infection after kidney transplantation. The study will be conducted at multiple study sites in several countries including Australia and Japan. Subjects who meet eligibility criteria will be enrolled in the study and will be randomized and assigned to BCV or SOC (defined as use of the same immunosuppressant administered during prescreening) before receipt of the first dose of study drug in both the Dose Escalation Phase and the Expansion Phase.

开始日期2022-10-14

申办/合作机构

SymBio Pharmaceuticals Ltd.

100 项与 Brincidofovir 相关的临床结果

登录后查看更多信息

100 项与 Brincidofovir 相关的转化医学

登录后查看更多信息

100 项与 Brincidofovir 相关的专利（医药）

登录后查看更多信息

378

项与 Brincidofovir 相关的文献（医药）

2026-01-01·PLANT SCIENCE

MdBACT5 and MdBACT8 contribute to the formation of branched-chain volatiles in apple

Article

作者: Li, Haotong ; Qin, Chu ; Yang, Xinhui ; Yu, Yumeng ; Li, Xin

Branched-chain amino acid aminotransferases (BCATs) catalyze both the final anabolic step and the initial catabolic step of branched-chain amino acids (BCAAs), which are pivotal for the formation of plant branched-chain volatiles (BCVs). However, the members of BCAT family in apple (Malus domestica Borkh.) remain poorly characterized. In the current study, we identified nine BCAT genes in the apple genome. Phylogenetic analysis classified these MdBCATs into two groups distributed across five chromosomes, with conserved gene structures within each group. Physicochemical analysis revealed coding sequence (CDS) lengths ranging from 852 to 1248 bp, encoding proteins with molecular weights of 31.13 45-41 kDa and isoelectric points (pI) of 5.86-8.35. Collinearity analysis indicated that segmental duplication predominantly drove the expansion of the apple BCAT family. Promoter regions of MdBCATs harbored cis-acting elements associated with growth and development, stress responses, and hormone signaling. RT-qPCR analysis demonstrated differential expression patterns of MdBCATs in the peel tissue of 'Oregon Spur II' apples during ambient storage. Subcellular localization revealed plastid- and mitochondrial-targeting of specific MdBCATs. Notably, transient overexpression of mitochondrially-localized MdBACT5 and MdBACT8 significantly enhanced BCV biosynthesis. Taken together, this study provides critical insights into the role of BCATs in apple fruit aroma quality.

2025-11-01·CURRENT MEDICINAL CHEMISTRY

Exploring the Dynamics of Asparagus racemosus Phytochemicals as Dual Target Inhibitors of Monkeypox Virus

Article

作者: Jardan, Yousef A. Bin ; Bourhia, Mohammed ; Mishra, Saurav Kumar ; Akash, Shopnil ; Singh, Nagendra ; Chandra, Anshuman ; Krishna, Nikita ; Georrge, John J. ; Mitra, Namrata

Aim::

This study aimed to screen the potential phytochemicals derived from Asparagus racemosus (Shatavari) against Thymidylate Kinase (TMPK) and D9 decapping enzyme, which is the vital target of the monkeypox virus and helps in the host-- pathogen interaction mechanism, using integrated docking, QSAR analysis, and a molecular dynamics approach.

Background::

The Monkeypox Virus (MPXV) is a recently emerging outbreak with ongoing infection cases. Drugs and vaccines for smallpox are being used to contain it. However, no specific drugs or vaccines are available to combat this infection.

Methods::

The TMPK and D9 decapping enzymes were retrieved from the MPXV virus UK strain in FASTA format. Due to the unavailability of an experimentally determined structure, the 3D structure was modelled via SWISS-MODEL and further enhanced and validated. The structure was subjected to docking analysis with the derived phytochemicals from Asparagus racemosus using a maestro module. The potential inhibitors were examined via QSAR analysis. Additionally, through MD simulation 250ns, the stability was analyzed, and the MM-GBSA was employed to calculate the binding affinities.

Results::

The molecular investigation revealed asparoside-C (PubChem ID: 158598) and asparoside-D (PubChem ID: 158597) to be potential hits among others for both targets (TMPK and D9 decapping enzyme) compared to the reference drugs, i.e., tecovirimat, brincidofovir, and cidofovir, possessing antiviral and required bioactivity analyzed via the ADME and QSAR analyses. Moreover, the simulation study of over 250ns revealed strong stability, followed by RMSD, RMSF, etc. The free energy calculation via MMGBSA exhibited strong affinities of asparoside-C and asparoside-D towards the TMPK and the D9 decapping enzyme according to their respective scores.

Conclusion::

The docking, QSAR, and simulation investigation revealed dual-target inhibitors activity of phytochemicals from Asparagus racemosus towards the MPXV via targeting TMPK and D9 decapping enzyme. It has been observed that asparoside-D and asparoside-C can potentially combat MPXV.

2025-11-01·ANTIVIRAL RESEARCH

Small molecule direct-acting antivirals for treatment of mpox

Review

作者: Ruggiero, Lee ; Lanier, E Randall ; Demarest, James F ; Pottage, John C ; Mackman, Richard L

In 2022 and 2024, outbreaks of mpox disease caused by two different clades of MPXV resulted in the World Health Organization (WHO) declaring two public health emergencies of international concern (PHEIC). Different clades/subclades/lineages of MPXV can have substantially different pathogenicity and transmission characteristics. The recent rapid spread of mpox disease, evidence for evolution of MPXV during sustained human-human transmission, challenges associated with MPXV vaccination, and disappointing results from two Phase 3 trials of a promising antiviral (tecovirimat) highlight an urgent unmet need for mpox treatments. This review assesses the current landscape of small molecule direct acting antivirals (DAAs) for mpox in the context of potential pandemic threats from ORPVs. Despite many reports of compounds with antiviral activity against MPXV and other ORPVs in vitro, none have proven effective so far in controlled clinical human studies. To address this gap, tecovirimat is undergoing further testing in Phase 3 trials for mpox, as is a second small molecule DAA (brincidofovir), both approved by national regulatory agencies (e.g., U.S. FDA) for the treatment of smallpox based on efficacy in animal models. Additional DAAs for treatment of mpox are in early development, highlighting a major gap in medical countermeasures. Compound characteristics are identified that should increase the probability of clinical success and durability for mpox and improve the likelihood that they will also be effective against other ORPVs.

90

项与 Brincidofovir 相关的新闻（医药）

2025-09-17

·GlobeNewswire-Health Care

Emergent BioSolutions Secures $17 Million Contract Modification for Oral Suspension TEMBEXA® (brincidofovir), a Smallpox Antiviral, and Strengthens Overall U.S. Supply Chain

Sept. 15, 2025 -- Emergent BioSolutions Inc. (NYSE: EBS) today announced it has received a $17 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to supply TEMBEXA® (brincidofovir) oral suspension. This follows the U.S. Food and Drug Administration’s (FDA) recent approval of the manufacturing scale-up of TEMBEXA® oral suspension. Oral suspension formulation is an important option for patients who may have trouble swallowing due to age or medical status. “Our newly secured contract modification and ongoing collaboration with BARDA and its procurement of TEMBEXA® (brincidofovir) oral suspension formulation reinforces the critical need for a continuous supply of countermeasures to help address smallpox disease among vulnerable patient populations during a potential outbreak,” said Paul Williams, senior vice president, head of products business, global government & public affairs at Emergent. “We are proud of our efforts to increase manufacturing scale to respond to customers’ immediate needs by strengthening our U.S. manufacturing and supply chain process and serving as a trusted partner supporting the U.S. government to address this serious national health security threat.” This newly exercised contract modification (CLIN0004B) to supply TEMBEXA® builds upon the previously announced options (CLIN0004A and CLIN0005A) from September 2024, and are all under Emergent’s existing 10-year contract. This project has been funded in whole or in part with federal funds from the U.S. Department of Health and Human Services; Administration for Strategic Preparedness and Response; the Biomedical Advanced Research and Development Authority under contract number 75A50122C00047. TEMBEXA® is an oral antiviral approved by the FDA in June 2021 for the treatment of human smallpox disease caused by variola virus in adult and pediatric patients, including neonates. TEMBEXA® is formulated as 100 mg tablets and 10 mg/mL oral suspension dosed once weekly for two weeks. The oral suspension formulation is particularly important for patients who have difficulty swallowing due to age or medical status. At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. The content above comes from the network. if any infringement, please contact us to modify.

上市批准

2025-07-28

·GlobeNewswire-Health Care

New Publication in Expert Review of Anti-infective Therapy Evaluates Brincidofovir as Potential Antiviral Treatment for Mpox

Ongoing mpox outbreak continues to be a global health threat and is driving need for greater therapeutic research and innovationGAITHERSBURG, Md., July 28, 2025 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the publication of a comprehensive review article, "Brincidofovir in the Era of Mpox," in the peer-reviewed journal Expert Review of Anti-infective Therapy.1 This publication includes an overview of brincidofovir, in vitro and in vivo data, including human case studies of the investigational use of brincidofovir, the current evaluation for treating mpox infections in adults and pediatrics in the Democratic Republic of Congo, and the potential for combination therapy with tecovirimat for immunocompromised patients with severe disease. “We believe in the importance of assessing brincidofovir, an antiviral, for this public health threat and we look forward to advancing our research across mpox as it’s a global disease of increasing concern,” said Simon Lowry, M.D., chief medical officer and head of research and development at Emergent. Mpox, formerly known as monkeypox, continues to pose a significant public health challenge, with ongoing regional and global outbreaks particularly in Central and West Africa. On August 14, 2024, the World Health Organization (WHO) declared the current mpox outbreak a global Public Health Emergency of International Concern (PHEIC).2 This marks the second mpox PHEIC declared by the WHO in the past two years, which followed the regional emergency declaration by the Africa Centres for Disease Control and Prevention (Africa CDC) on August 13, 2024.3 This month, the U.S. Centers for Disease Control and Prevention issued an updated report on the surge of mpox around the world.4 As part of the ongoing effort to identify safe and effective treatments for mpox, brincidofovir is currently being evaluated by the Africa CDC in partnership with PANTHER (PANdemic preparedness plaTform for Health and Emerging infectious Response) in the MpOx Study in Africa (MOSA), a double-blind, placebo-controlled clinical trial for people diagnosed with mpox, which initiated in January 2025. The study has received initial funding from Horizon Europe and Africa CDC. Dr. Lowry continued, “In addition to our engagement with PANTHER on the MOSA trial, this scientific review provides insights into the investigational use of brincidofovir in the treatment of mpox, and we are pleased this publication is available for the broader medical community.” Please see full Prescribing Information for TEMBEXA® (brincidofovir) for additional safety information.About Emergent BioSolutions At Emergent, our mission is to protect and save lives. For over 25 years, we’ve been at work preparing those entrusted with protecting public health. We deliver protective and life-saving solutions for health threats like smallpox, mpox, botulism, Ebola, anthrax and opioid overdose emergencies. To learn more about how we help prepare communities around the world for today’s health challenges and tomorrow’s threats, visit our website and follow us on LinkedIn, X, Instagram, Apple Podcasts and Spotify. Safe Harbor StatementWe generally identify forward-looking statements by using words like “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “should,” “will,” “would,” and similar expressions or variations thereof, or the negative thereof, but these terms are not the exclusive means of identifying such statements. Forward-looking statements are based on our current intentions, beliefs, and expectations regarding future events based on information that is currently available. We cannot guarantee that any forward-looking statement will be accurate. Readers should realize that if underlying assumptions prove inaccurate or if known or unknown risks or uncertainties materialize, actual results could differ materially from our expectations. Readers are, therefore, cautioned not to place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as of the date of this press release, and, except as required by law, we do not undertake to update any forward-looking statement to reflect new information, events, or circumstances. Readers should consider this cautionary statement, as well as the risk factors identified in our periodic reports filed with the U.S. Securities and Exchange Commission, when evaluating our forward-looking statements. Investor Contact:Richard S. LindahlExecutive Vice President, CFOlindahlr@ebsi.com Media Contact:Assal HellmerVice President, Communicationsmediarelations@ebsi.com __________________________ 1 https://doi.org/10.1080/14787210.2025.25320292 https://www.who.int/news/item/14-08-2024-who-director-general-declares-mpox-outbreak-a-public-health-emergency-of-international-concern3 https://africacdc.org/news-item/africa-cdc-declares-mpox-a-public-health-emergency-of-continental-security-mobilizing-resources-across-the-continent/ 4 https://www.cdc.gov/mpox/situation-summary/index.html

临床研究

2025-03-10

·生物制药小编

误打误撞开发的管线，现在要被收购

近日，Jazz Pharmaceuticals斥资9.35亿美元收购了Chimerix公司，这次收购的主要目标是为了Chimerix公司即将上市的管线Dordaviprone（ONC201）。早先我们曾经介绍过这款核心管线，本文将简单对此进行回顾，并结合Dordaviprone的传奇经历来说明Chimerix这家当初核心管线折戟的公司是怎么起死回生的。 Dordaviprone的峰回路转 Chimerix最初并不开发Dordaviprone，Dordaviprone是这家公司从另外一家私营Biotech Oncoceutics手中买下的。从一些更早期的信息来看，Dordaviprone（ONC201）最早可以追溯到Boehringer Ingelheim 1973年的小分子化合物TIC10。Dordaviprone本身是一种多巴胺受体D2/D3抑制剂和线粒体酪蛋白水解蛋白酶P（CIpP）变构激动剂。因为多巴胺受体抑制剂的性质，最初是打算将用于精神相关疾病的（比如说癫痫），但后续的研究人员发现这种小分子还可以穿透血脑屏障，因此他们就将其用于脑瘤开发。滨州州立大学得到TIC10后，将其转让给了Oncoceutics交给他们开发脑瘤。比较有趣的是，Boehringer Ingelheim在当初申请专利的时候搞错了分子结构，专利申请的化合物本身是没有抗肿瘤活性的，但后续其他研究团队发现，实际上用Boehringer Ingelheim的工艺会得到另外一种有抗肿瘤活性的化合物，而这种化合物才是真正的ONC201。虽然这一问题造成了专利战的波澜，但是最终无伤大雅。在临床开发中，ONC201选择了脑瘤中占据不小比例的胶质母细胞瘤（GBM）作为适应症，但临床最终失败，并没能改善患者的无进展生存期（PFS）。好在天无绝人之路。在这项试验的两个GBM组中，四名偶然入选的H3K27M突变患者中有两名表现出多处病变的持续消退。后续的多项在H3K27M突变患者中的临床轶事和肿瘤消退也证明了其疗效。这就使得研究人员将注意力转移到H3K27M突变上。不过Oncoceutics还没开发完，21年年初就被这次收购的主角Chimerix买下了。实际上Chimerix买下Oncoceutics可以说是抓住了救命稻草。抗病毒制药公司的转生 Chimerix的成立时间其实很早，2000年。这家公司最初致力于利用其专有脂质缀合技术开发抗病毒药物。公司早先侧重的是CMX001（brincidofovir），这是Cidofovir（西多福韦）的一种衍生物，通过抑制病毒DNA聚合酶来阻止病毒DNA的复制。它是Cidofovir的亲脂性形式，具有更好的细胞内吸收和更少的肾毒性。 CMX001最初在严重腺病毒感染和巨细胞病毒感染等临床研究开发失败。后续相关合作方美国生物医学高级研究与开发管理局（BARDA）找上门来，主打开发天花。不过Chimerix走的基本上是对外授权的路子，权益出售给了Emergent BioSolutions。CMX001（brincidofovir）虽然上市，Chimerix并没有拿到什么资金大头。几乎是与此同时，Chimerix开始主打开发公司另外一款管线dociparstat sodium (DSTAT) ，同样这也是从另外一家公司Cantex制药手中买来的，DSTAT本身是一种低抗凝肝素，具有多种作用机制，包括抑制 CXCR4/CXCL12 轴、阻断 HMGB1 和结合血小板因子 4 (PF-4)。 Chimerix最初是对DSTAT抱有很大期待的，时值新冠疫情爆发，DSTAT被开发用于新冠紧急损伤和AML，但是后续开发就相当令人失望。推进到III期临床后，2022年第一季度突然就放弃开发了。公司股价当时大跌60%。而2021年初买下的ONC201这时候接过大棒，成为公司主推。而现在，随着Dordaviprone上市在即，Chimerix公司成功实现了溢价变现，这对于成立多年的Chimerix也算是个好结局。参考来源： https://ir.chimerix.com/news-releases/news-release-details/chimerix-reports-fourth-quarter-and-year-end-2021-financial 绝命脑癌的一线生机 Pharmacophore Reassignment for Induction of the Immunosurveillance Cytokine TRAIL DOI:10.1002/anie.201402133

并购专利到期

100 项与 Brincidofovir 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D10547	Brincidofovir	J05A	DB12151

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
天花	美国	Emergent BioDefense Operations Lansing, Inc.	2021-06-04
天花	美国	Emergent Biodefense Operations Lansing LLC	2021-06-04

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肾盂肾炎	临床3期	美国	Chimerix, Inc.	2015-09-01
腺病毒感染	临床3期	美国	Chimerix, Inc.	2014-03-01
巨细胞病毒血症	临床3期	美国	Chimerix, Inc.	2013-08-01
巨细胞病毒血症	临床3期	比利时	Chimerix, Inc.	2013-08-01
巨细胞病毒血症	临床3期	加拿大	Chimerix, Inc.	2013-08-01
结外NK-T细胞淋巴瘤	临床2期	中国	SymBio Pharmaceuticals Ltd.	2025-06-09
结外NK-T细胞淋巴瘤	临床2期	日本	SymBio Pharmaceuticals Ltd.	2025-06-09
结外NK-T细胞淋巴瘤	临床2期	新加坡	SymBio Pharmaceuticals Ltd.	2025-06-09
肾脏疾病	临床2期	日本	SymBio Pharmaceuticals Ltd.	2022-10-14
腺病毒科感染	临床2期	美国	SymBio Pharmaceuticals Ltd.	2021-08-16

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04706923 (ATHENA, Tandem Meetings ASTCT and CIBMTR2024) 人工标引	临床2期	腺病毒科感染	27	Brincidofovir IV 0.2 mg/kg	積艱網蓋鑰鹽鏇衊簾築(網蓋窪構淵鑰繭膚築淵) = 範窪壓憲鑰鹽鬱餘鬱壓築艱鏇憲廠範憲艱範醖 (鑰鹹選糧獵築鏇夢獵築 ) 更多	积极	2024-02-01
				Brincidofovir IV 0.3 mg/kg	積艱網蓋鑰鹽鏇衊簾築(網蓋窪構淵鑰繭膚築淵) = 廠窪繭糧範鬱積醖夢鹹築艱鏇憲廠範憲艱範醖 (鑰鹹選糧獵築鏇夢獵築 ) 更多
NCT01143181 (CTgov)	临床3期	DNA病毒感染	210	BCV (BCV (≤4 mg/kg/Week))	觸顧齋蓋獵蓋築顧顧積 = 鑰鑰製餘鏇觸選衊襯淵網鏇鏇糧構遞鹽顧築夢 (蓋壓夢構鹽獵獵蓋願壓, 鏇窪夢簾遞醖簾觸願壓 ~ 糧蓋窪顧鏇繭夢選顧鑰) 更多	-	2021-08-12
				BCV (BCV (>4 mg/kg/Week))	觸顧齋蓋獵蓋築顧顧積 = 鏇鹹鹽醖醖夢壓憲遞襯網鏇鏇糧構遞鹽顧築夢 (蓋壓夢構鹽獵獵蓋願壓, 壓壓遞衊製糧獵網積鏇 ~ 範淵餘顧糧艱鑰艱淵齋) 更多
NCT01241344 (CTgov)	临床2期	腺病毒科感染	52	Placebo	夢醖網獵築鏇廠製願齋 = 網夢觸齋網顧膚艱鹽襯艱網糧鑰鏇鹽鑰餘齋繭 (鏇遞廠壓範鹹範蓋網醖, 衊鹹醖遞繭遞憲積獵遞 ~ 壓淵鹽壓窪範鑰鏇遞遞) 更多	-	2021-07-16
NCT02439957 (CTgov)	临床3期	巨细胞病毒感染 \| 肾盂肾炎	6	Brincidofovir (Treatment 1)	構窪鹽窪遞廠壓製築淵(艱築艱簾範鬱遞蓋艱鬱) = 淵範艱積襯願壓醖蓋遞觸醖鑰積網憲淵築糧簾 (鏇選繭壓壓遞範顧網鬱, 窪鹹憲製鹹窪襯鹹範鑰 ~ 壓顧鹽繭獵鑰鬱鹹鬱鏇) 更多	-	2021-07-16
				Valganciclovir (Treatment 2)	構窪鹽窪遞廠壓製築淵(艱築艱簾範鬱遞蓋艱鬱) = 網醖壓艱蓋餘壓範獵鑰觸醖鑰積網憲淵築糧簾 (鏇選繭壓壓遞範顧網鬱, 願築壓獵範鬱廠範網製 ~ 壓觸醖選選餘獵築獵壓) 更多
NCT02439970 (SUSTAIN, CTgov)	临床3期	巨细胞病毒血症 \| 巨细胞病毒感染	5	Brincidofovir (Treatment 1)	製餘廠憲繭齋顧遞鏇蓋(鹽選齋憲衊衊構齋膚糧) = 夢膚鏇艱築襯積餘鹽膚網齋範齋憲簾構壓襯襯 (憲衊遞鏇襯築襯遞獵糧, 鑰壓夢鑰齋衊願餘憲憲 ~ 選齋鬱構積淵顧餘網遞) 更多	-	2021-07-16
				Valganciclovir (Treatment 2)	製餘廠憲繭齋顧遞鏇蓋(鹽選齋憲衊衊構齋膚糧) = 網積壓壓顧膚構淵糧簾網齋範齋憲簾構壓襯襯 (憲衊遞鏇襯築襯遞獵糧, 淵鹽顧範鹽膚糧鏇艱蓋 ~ 繭壓鏇蓋範衊鬱鬱選醖) 更多
NCT03339401 (AdAPT, CTgov)	临床2期	腺病毒感染	29	Brincidofovir (Brincidofovir)	簾製範淵艱選餘製廠鬱(顧淵衊衊積憲齋艱鏇糧) = 壓觸夢膚網鬱範簾選網壓襯齋觸鹹襯顧顧積餘 (夢鹽鬱築選獵艱齋繭選, 範窪網衊繭鬱鏇蓋齋積 ~ 構膚顧艱顧遞觸鏇廠鬱) 更多	-	2021-01-25
				Standard of Care (Standard of Care)	簾製範淵艱選餘製廠鬱(顧淵衊衊積憲齋艱鏇糧) = 範獵選衊襯糧窪鑰鑰淵壓襯齋觸鹹襯顧顧積餘 (夢鹽鬱築選獵艱齋繭選, 築繭顧齋構觸廠齋選淵 ~ 憲製願壓構選衊鏇醖願) 更多
NCT01769170 (CTgov)	临床3期	巨细胞病毒血症 \| 巨细胞病毒感染	452	Brincidofovir (Brincidofovir)	願夢顧鹹遞鬱廠範構鹽 = 積鬱憲鹽範繭醖廠淵選鑰網範膚範夢壓餘艱鬱 (襯選齋鑰鏇構糧鹽淵襯, 夢遞憲壓醖夢範簾憲簾 ~ 範廠願餘膚夢壓範醖鬱) 更多	-	2021-01-05
				Placebo (Placebo)	願夢顧鹹遞鬱廠範構鹽 = 壓鹹鹹襯膚網選壓鑰網鑰網範膚範夢壓餘艱鬱 (襯選齋鑰鏇構糧鹽淵襯, 範鹽窪餘鑰鏇遞獵齋鬱 ~ 襯範鑰壓衊襯膚鬱構製) 更多
EBMT2020	N/A	腺病毒科感染	28	Brincidofovir	範繭壓蓋遞網範獵窪範(艱艱鹽餘範鑰鹹憲鹹廠) = We registered 47 ADV infection episodes with positive viremia (median peak: 1.077.546 copies/mL, range: 15.100-75.000.000) 範廠繭觸觸範壓選願醖 (鑰醖簾製襯鏇遞簾鹽艱 ) 更多	积极	2020-08-29
Not applicable (EBMT2019)	N/A	-	24	Brincidofovir	壓夢鏇糧淵願觸網廠製(鬱積鏇襯憲選蓋醖獵鹹) = 窪構築選願鏇齋鹽襯顧遞鑰獵鹹齋製艱製網艱 (壓遞醖廠觸繭餘願醖鹹 )	积极	2019-03-24
NCT01769170 (Pubmed \| Biol Blood Marrow Transplant)	临床3期	-	452	Brincidofovir	鹽遞構製鏇築蓋網膚構(醖憲壓艱遞糧製顧築糧) = 餘壓衊構餘壓觸觸壓顧選夢餘繭鹹網積窪齋製 (觸鹽鬱膚鏇鏇蓋積簾齋 ) 更多	不佳	2019-02-01
				Placebo	鹽遞構製鏇築蓋網膚構(醖憲壓艱遞糧製顧築糧) = 艱鏇鏇鬱顧鹽鹽範窪醖選夢餘繭鹹網積窪齋製 (觸鹽鬱膚鏇鏇蓋積簾齋 ) 更多